ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023

On October 17, 2023 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported that the company will present two poster presentations at the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2023 taking place October 20-24, 2023, in Madrid, Spain (Press release, ORIC Pharmaceuticals, OCT 17, 2023, View Source [SID1234636070]). The presentations will highlight the initial Phase 1b clinical data for ORIC-114 in EGFR/HER2 exon 20 mutated cancers and new preclinical data for ORIC-114 demonstrating activity against additional atypical mutations in EGFR.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In conjunction with the ESMO (Free ESMO Whitepaper) presentations, ORIC will host a conference call and webcast on Saturday, October 21, 2023, at 9:00 a.m. ET. Management will be joined by Dr. Alexander Spira, Clinical Director, NEXT Oncology-Virginia, who will share his perspective on the initial data from the Phase 1b study and the potential of ORIC-114 to treat EGFR/HER2 exon 20 mutated cancers.

Details of the ESMO (Free ESMO Whitepaper) poster presentations are as follows:

Title: A Global Phase 1b Study of ORIC-114, a Highly Selective, Brain Penetrant EGFR and HER2 Inhibitor, in Patients with Advanced Solid Tumors Harboring EGFR Exon 20 or HER2 Alterations
Poster #: 1333P
Poster Session: NSCLC, metastatic
Date & Time: Monday, October 23, 2023, at 9:00 a.m. CEST

Title: Preclinical Activity of ORIC-114, a Highly Selective, Brain Penetrant,
Irreversible Kinase Inhibitor, Against Atypical Mutations in EGFR
Poster #: 1345P
Poster Session: NSCLC, metastatic
Date & Time: Monday, October 23, 2023, at 9:00 a.m. CEST

Full abstracts are available for public viewing via the ESMO (Free ESMO Whitepaper) website. ePosters will be available Saturday, October 21, 2023, at 9:00 a.m. CEST.

Conference Call and Webcast Details

To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. A live webcast and audio archive of the conference call will be available through the investor section of the company’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.